A clinical trial of antazoline in the treatment of arrhythmias

Reynolds, Ernest W.; Baird, Walter M.; Clifford, Mary

doi:10.1016/0002-9149(64)90035-9

Cited by 24 publications

(15 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Well -known mild adverse effects of antazoline such as hot flush, metallic taste, or drowsiness were not consistently reported in medical documentation and therefore were not analyzed in this study. 8,10,12,15 An interesting finding of the study was a relatively high proportion of patients with documented CAD or structural heart disease in the antazoline group (TABLE 1). Propafenone had been administered more reluctantly in those patients, which is understandable in the light of clinical guidelines.…”

Section: Acknowledgmentsmentioning

confidence: 89%

“…2,3 Patients with structural heart disease were included or excluded from the previous antazoline studies depending on the publication: for instance, structural heart disease was an exclusion criterion in the AnPAF trial. 8,10,12,16 The general effectiveness and safety of antazoline in those groups of patients remain unclear and warrant further research.…”

Section: Acknowledgmentsmentioning

confidence: 99%

“…The statistical software package SAS properties. [6][7][8] Clinically, antazoline is considered to lower the velocity of intraatrial conduction, prolong the atrial refraction period, and improve atrioventricular conduction, allowing a fast ventricular response to supraventricular arrhythmias. In human healthy volunteers, the terminal elimination half -life of antazoline was 2.29 hours with a mean residence time of 3.45 hours and no data on hemodynamic effects of antazoline yet published.…”

mentioning

confidence: 99%

“…9 In clinical practice, the drug can be administered intravenously in boluses of 50 to 100 mg every 3 to 5 minutes until successful cardioversion or up to a cumulative dose of 250 to 350 mg. [10][11][12] While not mentioned in relevant clinical guidelines, published observational studies have suggested high efficacy of antazoline, ranging between 50% and 80% and a rapid onset of action with cardioversion times between 7 and 20 minutes. 8,[10][11][12][13][14][15] However, there have been no studies examining the comparative effectiveness and safety of antazoline and antiarrhythmic drugs recommended by clinical guidelines. 2,3 The aim of the study was to examine the comparative effectiveness and safety of antazoline--based and propafenone -based strategies for a pharmacological cardioversion of short -duration AF in the emergency department of our center.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department

Farkowski¹,

Maciąg²,

Zurawska³

et al. 2016

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Section: Acknowledgmentsmentioning

confidence: 89%

Section: Acknowledgmentsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department

Farkowski¹,

Maciąg²,

Zurawska³

et al. 2016

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

“…Antazoline is an antihistaminic agent with antiarrhythmic quinidine-like properties [2][3][4]. In some countries it is registered for intravenous termination of cardiac arrhythmias and has been successfully used for many years for rapid termination of AF [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Antazoline for rapid termination of atrial fibrillation during ablation of accessory pathways

Piotrowski

Kryński

Futyma³

et al. 2014

Cardiol J

View full text Add to dashboard Cite

Background and aim: To assess safety and efficacy of antazoline for termination of atrial fibrillation (AF) occurring during ablation of accessory pathways (AP). Methods: We analyzed electrophysiological mechanism of antazoline (changes in A-A interval) and the percentage of pre-excited QRS complexes before and after antazoline administration. The total dose administered and the time from the start of injection to sinus rhythm restoration were also measured. (Cardiol J 2014; 21, 3: 299-303) Results: Out of consecutive 290 patients with Wolff-Parkinson-White syndrome undergoing radiofrequency (RF) ablation, 12 (4.1%) (4 females, mean age 36 ± 20 years) developed sustained AF which did not stop spontaneously within 10 min, and antazoline in 100 mg repeated boluses was administered. In all 12 patients the drug restored sinus rhythm after a mean of 425 ± 365 s (range 43-1245 s) using a mean cumulative dose of 176 ± 114 mg (range 25-400 mg). The drug slightly prolonged R-R intervals during AF (from 383 ± 106 to 410 ± ± 70 ms) and reduced the percentage of fully pre-excited QRS complexes (from 35% to 26%). Intracardiac recordings showed gradual increase in A-A intervals, as well as regularization and decreasing fractionation of atrial activity following drug injection (mean A-

show abstract

Determination of antazoline hydrochloride in rat plasma and excreta by reversed‐phase ion‐pair chromatography and its application to pharmacokinetics

Rui

Chu

et al. 2013

Biomedical Chromatography

View full text Add to dashboard Cite

A reversed-phase ion pair chromatography method with liquid-liquid extraction analytical method was developed and validated for the determination of antazoline hydrochloride in plasma and excreta of rat. The aim of our study was to characterize the preclinical pharmacokinetics and excretion profiles of antazoline hydrochloride in rats after intravenous injection at the dose of 10 mg/kg. Plasma and excreta samples were extracted with ethyl acetate, and phenacetin was used as the internal standard. The result showed that the method is suitable for the quantification of antazoline hydrochloride in plasma and excreta samples. Analysis of accuracy (90.89-112.33%), imprecision (<7.1%) and recovery (>82.5%) showed adequate values. After a single intravenous administration at 10 mg/kg to rats, plasma concentration profile showed a relative fast elimination proceeding with a terminal elimination half-life of 3.53 h. Approximately 61.8 and 14.2% of the administered dose were recovered in urine and bile after 72 and 24 h post-dosing respectively; 5.9% of the administered dose was recovered in feces after 72 h post-dosing. The above results show that the major elimination route is urinary excretion.

show abstract

A clinical trial of antazoline in the treatment of arrhythmias

Cited by 24 publications

References 6 publications

Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department

Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department

Antazoline for rapid termination of atrial fibrillation during ablation of accessory pathways

Determination of antazoline hydrochloride in rat plasma and excreta by reversed‐phase ion‐pair chromatography and its application to pharmacokinetics

Contact Info

Product

Resources

About